These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35115074)

  • 41. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
    Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
    CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Deep Brain Stimulation as a Rescue When Duodenal Levodopa Infusion Fails.
    Nathoo N; Sankar T; Suchowersky O; Ba F
    Can J Neurol Sci; 2019 Jan; 46(1):130-131. PubMed ID: 30688202
    [No Abstract]   [Full Text] [Related]  

  • 43. Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?
    Picconi B; Calabresi P
    Mov Disord; 2014 May; 29(6):715-9. PubMed ID: 24591264
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Incidence and determinants of levodopa-induced dyskinesia in a retrospective cohort of Mexican patients with Parkinson's disease].
    Cervantes-Arriaga A; Rodríguez-Violante M; Salmerón-Mercado M; Calleja-Castillo J; Corona T; Yescas P; Alonso-Vilatela E
    Rev Invest Clin; 2012; 64(3):220-6. PubMed ID: 23045943
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
    LeWitt PA
    Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Web Resource for Levodopa-Induced Dyskinesia Genetics in Parkinson's Disease.
    Blankenburg H; Falla M; Schwienbacher C; Fabbrini G; Berardelli A; Pramstaller PP; Domingues FS
    Neuroinformatics; 2017 Jul; 15(3):297-300. PubMed ID: 28417316
    [No Abstract]   [Full Text] [Related]  

  • 47. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
    Horstink MW; Zijlmans JC; Pasman JW; Berger HJ; van't Hof MA
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):224-6. PubMed ID: 2324754
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
    Herring WJ; Assaid C; Budd K; Vargo R; Mazenko RS; Lines C; Ellenbogen A; Verhagen Metman L
    Clin Neuropharmacol; 2017; 40(6):255-260. PubMed ID: 29059133
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
    Varanese S; Howard J; Di Rocco A
    Mov Disord; 2010 Mar; 25(4):508-10. PubMed ID: 20014061
    [No Abstract]   [Full Text] [Related]  

  • 51. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease.
    Manson AJ; Iakovidou E; Lees AJ
    Mov Disord; 2000 Mar; 15(2):336-7. PubMed ID: 10752589
    [No Abstract]   [Full Text] [Related]  

  • 52. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
    Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Dyskinesia caused by L-DOPA].
    Derkinderen P; Vidailhet M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rhabdomyolysis induced by severe levodopa induced dyskinesia in a patient with Parkinson's disease.
    Lyoo CH; Lee MS
    J Neurol; 2011 Oct; 258(10):1893-4. PubMed ID: 21499722
    [No Abstract]   [Full Text] [Related]  

  • 55. Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Kwak N; Park J; Kang HY; Lee MJ; Suh JK; Lee H
    J Parkinsons Dis; 2022; 12(3):773-783. PubMed ID: 35180134
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
    Cheshire PA; Williams DR
    J Clin Neurosci; 2012 Mar; 19(3):343-8. PubMed ID: 22249009
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Direct relief of levodopa-induced dyskinesia by stimulation in the area above the subthalamic nucleus in a patient with Parkinson's disease--case report.
    Nishikawa Y; Kobayashi K; Oshima H; Fukaya C; Yamamoto T; Katayama Y; Ogawa A; Ogasawara K
    Neurol Med Chir (Tokyo); 2010; 50(3):257-9. PubMed ID: 20339282
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
    Zesiewicz TA; Sullivan KL; Hauser RA
    Curr Neurol Neurosci Rep; 2007 Jul; 7(4):302-10. PubMed ID: 17618536
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
    Rascol O; Fox S; Gasparini F; Kenney C; Di Paolo T; Gomez-Mancilla B
    Parkinsonism Relat Disord; 2014 Sep; 20(9):947-56. PubMed ID: 24951359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.